Royal London Asset Management LTD Seagen Inc. Transaction History

Royal London Asset Management LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $773,125 - $872,637	4,037 Added 7.97%	54,659 $11.6 Million
Q2 2023 Aug 11, 2023	BUY	$187.64 - $206.25 $548,096 - $602,456	2,921 Added 6.12%	50,622 $9.74 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $224,813 - $357,826	1,762 Added 3.84%	47,701 $9.66 Million
Q4 2022 Feb 09, 2023	BUY	$117.37 - $139.17 $136,501 - $161,854	1,163 Added 2.6%	45,939 $5.9 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $587,883 - $782,758	-4,346 Reduced 8.85%	44,776 $6.13 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $127,863 - $168,741	1,069 Added 2.22%	49,122 $7.08 Million
Q2 2021 Oct 18, 2022	SELL	$135.08 - $161.1 $144,400 - $172,215	-1,069 Reduced 2.18%	48,053 $7.58 Million
Q1 2021 Oct 17, 2022	SELL	$137.51 - $190.8 $146,998 - $203,965	-1,069 Reduced 2.18%	48,053 $6.68 Million
Q1 2021 Apr 13, 2021	BUY	$137.51 - $190.8 $305,822 - $424,339	2,224 Added 4.85%	48,053 $6.67 Million
Q4 2020 Jan 29, 2021	BUY	$164.63 - $211.93 $7.54 Million - $9.71 Million	45,829 New	45,829 $8.03 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Royal London Asset Management LTD with notifications on news.